EPO and chronic kidney disease: However, we did not measure novel circulating markers associated with erythropoietin resistance such as pro-hepcidin which may be a marker for inflammation and alter iron availability [13]–[15], soluble transferrin receptor which has been shown to be decreased in chronic kidney disease [16]–[19], and C-reactive protein (CRP).